On 26 January 2011 the US Food and Drug Administration (FDA) announced a safety communication to warn about an association between breast implants and anaplastic large cell lymphoma. The risk of a patient developing this type of lymphoma is very low.
The Therapeutic Goods Administration (TGA) has been monitoring the situation and has been in communication with the FDA and specialist groups over the past year on the issue.
The Australian Society of Plastic Surgeons posted guidance for patients on this issue in March 2010. Women with breast implants should continue to routinely monitor their breast implants and consult their implanting surgeon if they have any concerns. At this time, TGA does not recommend prophylactic breast implant removal in patients without symptoms or other abnormality – TGA report dated 27 January 2011.
Please find attached the following information:
Australian Society of Plastic Surgeons Media Release issued 27 January 2011 entitled “FDA safety signal on ALCL and breast implants”
Australian Society of Plastic Surgeons – A Guide for Patients
Breast Implants and Lymphoma Risk: A Review of the Epidemiologic Evidence Through 2008 by Loren Lipworth ScD, Robert E Tarone PhD and Joseph K McLaughlin PhD